NeuroOne Medical Technologies Corporation (NMTC)
| Market Cap | 7.08M -79.6% |
| Revenue (ttm) | 12.47M +88.1% |
| Net Income | -7.45M |
| EPS | -0.95 |
| Shares Out | 9.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 136,180 |
| Open | 0.8700 |
| Previous Close | 0.8852 |
| Day's Range | 0.7500 - 0.9800 |
| 52-Week Range | 0.7500 - 6.1200 |
| Beta | 0.90 |
| Analysts | Strong Buy |
| Price Target | 7.27 (+835.14%) |
| Est. Earnings | Dec 16, 2026 |
About NMTC
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company has a ... [Read more]
Financial Performance
In fiscal year 2025, NMTC's revenue was $12.10 million, an increase of 250.35% compared to the previous year's $3.45 million. Losses were -$3.61 million, -70.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NMTC stock is "Strong Buy." The 12-month stock price target is $7.27, which is an increase of 835.14% from the latest price.
News
NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System
Study Reports Immediate Pain Freedom in 14 of 15 Patients; all Patients Achieved Favorable Pain Outcomes at a Mean Six-Month Follow-Up Multi-Contact Probe Technology Enabled Mapping and Treatment of T...
NeuroOne Featured in New York Post on OneRF® Patient's Remarkable Journey to Overcome Debilitating Facial Pain
NeuroOne's FDA 510(k)-Cleared OneRF Trigeminal Nerve Ablation System Offers Hope for Patients Suffering from Trigeminal Neuralgia EDEN PRAIRIE, Minn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medica...
NeuroOne Medical secures first pharmaceutical purchase order for StereoCED
NeuroOne Medical (NMTC) announced that it has secured its first pharmaceutical industry purchase order for the StereoCED Drug Delivery Platform to support a preclinical animal research program for a g...
NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program
NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Research
NeuroOne Medical joins Dartmouth team on $1M NIH neurotransmitter sensing grant
NeuroOne Medical (NMTC) announced it has entered into a research and development subaward agreement with Dartmouth to support the advancement of next-generation neurotransmitter sensing technology. Re...
NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology
New NIH Award will Initially Provide NeuroOne Approximately $200,000 through April 2027 EDEN PRAIRIE, Minn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ...
NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range EDEN PRAIRIE, Minn., Oct. 05, 2026 (GLOBE NEWSW...
NeuroOne Medical enters OneRF Trigeminal Nerve Ablation System distribution pact
NeuroOne Medical (NMTC) announced a new Southern California distribution agreement for its FDA-cleared OneRF Trigeminal Nerve Ablation System. The agreement covers key counties, including the Los Ange...
NeuroOne Medical enters OneRF Trigeminal Nerve Ablation System distribution pact
NeuroOne Medical (NMTC) announced a new Southern California distribution agreement for its FDA-cleared OneRF Trigeminal Nerve Ablation System. The agreement covers key counties, including the Los Ange...
NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement
EDEN PRAIRIE, Minn., Sept. 17, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on transforming the...
NeuroOne Medical Technologies Transcript: Moody Capital Disruptive Growth & Life Science Conference
Strategic partnerships and proprietary thin film technology drive growth in epilepsy, pain, and drug delivery markets. Near-term catalysts include commercialization of drug delivery devices and expansion into BVNA, with revenue guidance of $9.2M–$10.5M this year.
NeuroOne Medical Technologies Slides: Corporate presentation
NeuroOne Medical Technologies has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
NeuroOne Medical price target lowered to $5 from $13 at Maxim
Maxim lowered the firm’s price target on NeuroOne Medical (NMTC) to $5 from $13 and keeps a Buy rating on the shares. The company reported Q3 results below consensus estimates,…
NeuroOne Medical Technologies Earnings Call Transcript: Q3 2026
Q3 FY2026 saw 16% revenue growth and 43% order growth, with gross margins rising to 59.9%. ISO 13485 certification enables international expansion, while new product and clinical milestones support future growth. Guidance for FY2026 revenue is $9.2–$10.5 million.
NeuroOne Medical Technologies Earnings release: Q3 2026
NeuroOne Medical Technologies released its Q3 2026 earnings on August 13, 2026, summarizing the period's financial results.
NeuroOne Medical Technologies Quarterly report: Q3 2026
NeuroOne Medical Technologies has published its Q3 2026 quarterly earnings report on August 13, 2026.
NeuroOne Medical Technologies Transcript: Planet MicroCap Las Vegas 2026
Innovative thin film and wire electrode technologies are driving less invasive, dual-purpose treatments for epilepsy and chronic pain, with strong clinical results and expanding market adoption. Financially stable with a cash runway through 2026, the company is poised for growth in new indications and international markets.
NeuroOne Medical Technologies Slides: Corporate presentation
NeuroOne Medical Technologies has posted slides in relation to its latest quarterly earnings report, which was published on June 12, 2026.
NeuroOne Medical target adjusted to $8 from $1.60 at Ladenburg
Ladenburg adjusted the firm’s price target on NeuroOne Medical (NMTC) to $8 from $1.60 and keeps a Buy rating on the shares. It cites the one-for-six reverse stock split for…
NeuroOne Medical Technologies Earnings Call Transcript: Q2 2026
Q2 FY2026 saw 72% YoY product revenue growth to $2.4M, driven by OneRF Brain Ablation sales and strong clinical adoption. Guidance for FY2026 remains $10.5M, excluding new product launches, with international expansion and drug delivery commercialization targeted for late 2026.
NeuroOne Medical Technologies Earnings release: Q2 2026
NeuroOne Medical Technologies released its Q2 2026 earnings on May 12, 2026, summarizing the period's financial results.
NeuroOne Medical Technologies Quarterly report: Q2 2026
NeuroOne Medical Technologies has published its Q2 2026 quarterly earnings report on May 12, 2026.
NeuroOne Medical Technologies trading halted, news pending
19:50 EDT NeuroOne Medical (NMTC) Technologies trading halted, news pending
NeuroOne Medical Technologies Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
A novel thin film electrode platform is driving growth in neurological device markets, with strong clinical outcomes, expanding partnerships, and a robust financial outlook. Key catalysts include new product launches, international expansion, and potential partnership deals in 2026.
NeuroOne Medical Technologies Transcript: Investor update
Four FDA-cleared devices target large neurological and pain markets, with strong partnerships and a unique thin-film platform driving growth. Fiscal 2026 revenue is guided at $10.5 million, with catalysts including new product launches, international expansion, and potential partnerships.